Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of Moderate Buy from Analysts

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) have earned an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average […]

Related Keywords

Annm Hanly , ,Endurance Cayman Ltd Svf ,Needham Company ,Metlife Investment Management ,Blackrock Inc ,Acadian Asset Management ,Goldman Sachs Group ,Vir Biotechnology Company Profile ,Nasdaq ,Dimensional Fund Advisors ,Jpmorgan Chase Co ,Securities Exchange Commission ,Vir Biotechnology Inc ,Vir Biotechnology ,Get Rating ,Marketbeat Ratings ,Ltd Svf ,Exchange Commission ,Asset Management ,Life Investment Management ,Fund Advisors ,Vir Biotechnology Daily ,Nasdaq Vir ,Ivir ,Medical ,Ratings ,Consensus ,